Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor

@inproceedings{Carroll2003RadiolabeledMA,
  title={Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor},
  author={Peter R. Carroll},
  year={2003}
}
Abstract Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, is highly expressed by virtually all prostate cancers. PSMA is also expressed on the tumor vascular endothelium of virtually all solid carcinomas and sarcomas but not on normal vascular endothelium. PSMA is currently the focus of several diagnostic and therapeutic strategies. We have previously reported on the radiolabeling and in vitro binding properties of monoclonal antibodies (mAbs) (J415, J533, and J591) that… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 72 CITATIONS, ESTIMATED 46% COVERAGE

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Metal-Based PSMA Radioligands

VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations